Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shire Builds Confidence In $20bn Revenue Target

Executive Summary

Shire's first investor R&D day after its major acquisition of Baxalta earlier this year saw management keen to "bring confidence to the $20bn revenue target figure that we have stated," said CEO Flemming Ornskov. Shire's hemophilia focus, in particular, is facing some scrutiny.

You may also be interested in...

Emicizumab Data Has Shire And Novo Looking Over Their Shoulders

Positive data from the HAVEN 1 Phase III study of Genentech's emicizumab put pressure on the hemophilia franchises of both Shire and Novo Nordisk.

Shire Exits Biosimilars, Streamlines Oncology Business

Terminating a pair of biosimilar partnerships inherited from Baxalta will better enable Shire to focus on core strengths, CEO Ornskov says. The firm will use Baxalta assets to gradually develop a cancer franchise.

Shire Plays Up Xiidra Launch, Downplays Missed Sales Expectations

Launched in August for dry eye disease, Xiidra already has seen nearly 65,000 prescriptions written and has captured 16% market share in the US. Overall quarterly sales came in below Wall Street expectations for Shire, but the firm says it was a strong quarter of execution.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts